This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis

This study has been completed.
Information provided by (Responsible Party):
Sharon Halton, The Methodist Hospital System Identifier:
First received: April 13, 2012
Last updated: May 3, 2012
Last verified: May 2012
The role of hyperlipidemia and lipid lowering therapy (LLT) in Amyotrophic Lateral Sclerosis (ALS) pathophysiology and its impact on disease progression and survival is unclear. The investigators analyzed the correlation between lipid levels with disease progression and survival in ALS patients and the association of LLT with these outcomes.

Amyotrophic Lateral Sclerosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Cohort Study of the Relationship of Hyperlipidemia and Statin Therapy on Survival and Disease Progresssion in Amyotrophic Lateral Sclerosis

Resource links provided by NLM:

Further study details as provided by Sharon Halton, The Methodist Hospital System:

Primary Outcome Measures:
  • survial(tracheostomy free,<23 hours on NIPPV, from enrollment) [ Time Frame: 3years ]
    Death was confirmed from Social Security Death Index or newspaper obituaries. Tracheostomy- ventilation was also considered as an end of the life time point.

Secondary Outcome Measures:
  • ALSFRS(measure of disability) [ Time Frame: at first evaluation(time 0-T0) to six months (T6) ]
    DeltaFS = (48-ALSFRS at first evaluation )/duration from onset to diagnosis (month) changeFS=(ALSFRS at six months-ALSFRS at first evaluation)/6

Biospecimen Retention:   Samples Without DNA

Enrollment: 267
Study Start Date: April 2008
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
lipid lowering therapy
those with lipid lowering therapy those without lipid lowering therapy


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
the Methodist Neurological Institute

Inclusion Criteria:

  • A clinical diagnosis of laboratory-supported probable, probable, or definite familial, sporadic ALS, according to a modified El Escorial criteria (ref), by the study investigators
  • Time from disease onset is less than three years

    • 18 years of age
  • Subjects with diagnosis of hyperlipidemia and/or taking lipid lowering medications will not be excluded from study.

Exclusion Criteria:

  • Requirement for tracheotomy ventilation or non-invasive ventilation for > 23 hours per day
  • Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease, etc)
  • A clinically significant history of significant medical illness (advanced cancer, chronic inflammatory/infectious conditions, etc) within six months of baseline
  • Use of progestins, anabolic steroids, and corticosteroids within 45 days of baseline visit. Therapy is allowed as medically indicated after baseline visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01592084

United States, Texas
the Methodist Neurological Institute
Houston, Texas, United States, 77030
Sponsors and Collaborators
The Methodist Hospital System
Study Director: Ericka P Simpson, M.D the Methodist Neurological Institute
  More Information

Responsible Party: Sharon Halton, Research Coordinator, The Methodist Hospital System Identifier: NCT01592084     History of Changes
Other Study ID Numbers: IRB(2)0609-0087
Study First Received: April 13, 2012
Last Updated: May 3, 2012

Keywords provided by Sharon Halton, The Methodist Hospital System:
lipid lowering therapy

Additional relevant MeSH terms:
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Lipid Metabolism Disorders processed this record on August 17, 2017